Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates

Core Insights - Immatics (IMTX) reported a quarterly loss of $0.66 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.38, marking a 73.68% earnings surprise [1] - The company's revenues for the quarter ended June 2025 were $5.38 million, missing the Zacks Consensus Estimate by 62.32%, and down from $20.19 million year-over-year [2] - Immatics has underperformed the market, with shares down about 9.7% year-to-date compared to the S&P 500's gain of 9.6% [3] Financial Performance - Over the last four quarters, Immatics has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $14.27 million, and for the current fiscal year, it is -$1.34 on revenues of $63.66 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Immatics belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Immatics' stock performance [5]